paclitaxel has been researched along with Angiogenesis, Pathologic in 239 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (4.60) | 18.2507 |
| 2000's | 101 (42.26) | 29.6817 |
| 2010's | 111 (46.44) | 24.3611 |
| 2020's | 16 (6.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, R; Bastian, A; Choudhary, S; Gangjee, A; Hamel, E; Ihnat, MA; Pavana, RK | 1 |
| Aguera, KN; Davis, GE; Griffin, CT; Kemp, SS; Koller, GM; Lin, PK; Salvador, J; Xie, J | 1 |
| Abd-Alhaseeb, MM; Mahmoud, MA; Okda, TM; Omran, GA | 1 |
| Niapour, A; Seyedasli, N | 1 |
| Li, T; Li, XT; Li, XZ; Wang, XL; Wang, XW; Wang, XX; Yang, JC; Yang, ZY; Zhao, R; Zhao, XR | 1 |
| Che, Z; Chen, D; Cui, J; Ding, K; Jiang, H; Li, A; Shu, Y; Xie, Z; Zhou, J; Zou, L | 1 |
| Fan, C; Lee, BH; Mo, C; Shetti, D; Wei, K; Zhang, B | 1 |
| Guan, J; Qian, J; Zhan, C | 1 |
| Herrmann, R; Holzgrabe, U; Polednik, C; Roller, J; Schmidt, M; Skaf, J | 1 |
| Español, AJ; Martínez Pulido, P; Salem, AR; Sales, ME; Sanchez, F; Sanchez, Y | 1 |
| Abe, T; Akino, T; Alam, MT; Ameda, K; Annan, DA; Azuma, M; Dawood, RIH; Harabayashi, T; Hida, K; Hida, Y; Ishizuka, K; Kashiwagi, A; Kikuchi, H; Maishi, N; Maruyama, S; Matsumoto, R; Matsuno, Y; Miyajima, N; Morimoto, M; Osawa, T; Sato, M; Shinohara, N; Takeda, R; Tsuchiya, K; Yamashiro, K | 1 |
| Cristofaro, I; Di Bari, M; Español, AJ; Salem, A; Sales, ME; Sanchez, Y; Tata, AM | 1 |
| Bai, X; Bei, Y; Cheng, N; Shen, P; Shu, Y; Song, Y; Xu, L; Yang, N; Zhang, W | 1 |
| Bian, Z; Liu, W; Liu, ZR; Mishra, F; Satyanarayana, G; Sharma, M; Sun, L; Turaga, RC; Yang, J; Yuan, Y | 1 |
| Chen, SR; Chen, YF; Cheng, YB; Lin, YC; Wang, SW; Yen, JY; Yu, CL | 1 |
| Annan, DA; Cong, L; Hida, K; Hida, Y; Maishi, N; Morimoto, H; Morimoto, M; Nam, JM; Young, MF | 1 |
| Aguilar, MR; Martín-Hita, A; Palao-Suay, R; Riestra-Ayora, J; Sánchez-Rodríguez, C; Sanz-Fernández, R; Yanes-Díaz, J | 1 |
| Andreucci, E; Barbato, G; Biagioni, A; Cianchi, F; Coratti, F; Giovannelli, L; Magnelli, L; Papucci, L; Peri, S; Schiavone, N; Staderini, F; Versienti, G | 1 |
| Bianco, R; Cantile, M; Chambery, A; Cicatiello, V; Ciciola, P; Collina, F; D'Amato, V; De Falco, S; De Placido, S; Di Bonito, M; Di Mauro, C; Formisano, L; Marciano, R; Orsini, RC; Rosa, R; Servetto, A; Veneziani, BM | 1 |
| Chen, S; Chen, X; Feng, Z; Li, J; Wu, X; Xu, J; Zhu, J | 1 |
| Hu, Y; Jiang, T; Jin, K; Liu, X; Luo, Z; Pang, Z; Shen, S; Tuo, Y; Wang, L; Zhang, B | 1 |
| Bijlsma, MF; Ebbing, EA; Krishnadath, KK; Mathôt, RAA; Medema, JP; Pistorius, MCM; Steins, A; van Laarhoven, HWM; Waasdorp, C; Wilmink, JW | 1 |
| Cao, D; Lei, M; Liang, L; Sun, J; Sun, Z; Wang, M; Wei, Y; Xu, Y | 1 |
| He, W; Li, S; Lv, Y; Xiao, Q; Yin, L; Zhao, X; Zhu, L | 1 |
| Li, Y; Mi, X; Niu, J; Song, Z; Zhang, Y | 1 |
| Alshangiti, A; Chandhoke, G; Ellis, PM | 1 |
| Dong, W; Jin, D; Li, L; Liu, Y; Meng, Y; Wang, H; Xia, X; Yang, Y; Ye, J | 1 |
| Barriuso, J; Berjón, A; Castelo, B; Crespo, R; Cruz, P; DE Molina, AR; Feliu, J; Hardisson, D; Heredia-Soto, V; Hernández, A; Herranz, J; Mendiola, M; Miguel-Martín, M; Peláez-García, A; Redondo, A; Yébenes, L | 1 |
| Barra, F; Casarin, J; Ferrero, S; Ghezzi, F; Laganà, AS | 1 |
| Cao, D; Huang, L; Kong, C; Li, H; Liang, L; Qin, H; Qu, X; Sun, Z; Wang, M; Wang, X; Xu, W; Yan, X; Zhang, Y | 1 |
| Abdi, R; Annabi, N; Bahmani, B; Banouni, N; Bromberg, JS; Eskandari, SK; Greiner, DL; Ichimura, T; Jiang, L; Kasinath, V; Li, X; Ordikhani, F; Shultz, LD; Uehara, M | 1 |
| Chow, A; Kerbel, RS; Khan, KA; Krüger, J; Man, S; Paez-Ribes, M; Pham, E; Wu, FTH; Xu, P | 1 |
| Du, S; Lu, Y; Xiong, H; Xu, C; Yao, J | 1 |
| Alsayed, A; He, C; Karginova, O; Lee, SS; Olopade, OI; Raoul, A; Weekley, CM; Wu, T | 1 |
| Hayashi, K; Iwasaki, H; Kataoka, H; Kitagawa, M; Natsume, M; Okamoto, Y; Okuda, Y; Shimura, T | 1 |
| Ishikura, N; Kurasawa, M; Sugimoto, M; Yamamoto, K; Yanagisawa, M; Yorozu, K | 1 |
| Nannuru, KC; Nawandar, DM; Sharma, B; Singh, RK; Varney, ML | 1 |
| Ahn, Y; Cho, HH; Hong, MH; Jeong, HY; Jeong, MH; Kang, WS; Kee, HJ; Kim, YS; Kwon, JS | 1 |
| Alani, AW; Mishra, GP; Nguyen, D | 1 |
| Alder, H; Baldassarre, G; Belletti, B; Califano, D; Canzonieri, V; Chiappetta, G; Cirombella, R; Croce, CM; Giglio, S; Losito, S; Lovat, F; Onesti, EC; Pellegrini, P; Pignata, S; Sonego, M; Sorio, R; Stoppacciaro, A; Vecchione, A; Volinia, S; Wernicke, D | 1 |
| Chen, M; Duan, H; Jiang, Z; Miao, J; Sun, L; Wang, Y; Wu, M; Zhang, L; Zhang, S; Zhang, X; Zhu, X | 1 |
| Artemov, D; Kato, Y; Zhu, W | 2 |
| Becker, S; Gellrich, D; Strieth, S | 1 |
| Chang, S; Liu, H; Pu, C; Sun, J; Wang, Z; Xu, RX; Zhu, S; Zhu, Y | 1 |
| Brown, NJ; Reed, MW; Staton, CA; Woll, PJ; Young, RJ | 1 |
| Aharon, A; Alishekevitz, D; Brenner, B; Bril, R; Fremder, E; Gingis-Velitski, S; Loven, D; Miller, V; Munster, M; Scherer, SJ; Shaked, Y; Voloshin, T | 1 |
| Chen, J; Hu, Y; Jiang, X; Liao, Z; Mei, H; Pang, Z; Shen, S; Shi, W; Wang, H; Wang, Y; Yang, J; Zhang, B | 1 |
| Chen, H; Chen, J; Feng, X; Gao, X; Hu, Q; Huang, M; Jiang, D; Jiang, X; Kang, T; Pang, Z; Song, Q; Yao, L; Zhang, X | 1 |
| Saeki, T; Ueda, S | 1 |
| Alama, A; Barletta, G; Biello, F; Boccardo, F; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Truini, A; Vanni, I | 1 |
| Chen, Y; Fan, J; Fu, S; Lin, S; Sun, X; Wan, Q; Wu, Z; Yang, B; Yang, L; Zou, X | 1 |
| Costa, VM; Diniz, C; Fresco, P; Soares, AS | 1 |
| Angelucci, A; Botta, L; Calgani, A; Delle Monache, S; Sanità, P; Schenone, S | 1 |
| Chen, P; Du, LC; Hu, HZ; Li, J; Li, YH; Luo, S; Tang, J; Wang, YS; Wei, YQ; Wen, YJ; Yang, DB; Zhang, P; Zhao, X | 1 |
| Li, W; Wan, L; Wang, J; Zhai, LY | 1 |
| Guo, F; He, S; Hu, Q; Jiang, W; Li, L; Lin, Z; Liu, X; Liu, Y; Ma, X; Sang, Y; Shen, G; Su, C; Wan, Y; Wang, Y; Wei, Y; Ye, T; Yin, T; Yu, M | 1 |
| Augustin, HG; Besemfelder, E; Hu, J; Jugold, M; Kapel, SS; Korn, C; Pasparakis, M; Savant, S; Srivastava, K; Teichert, M; Thomas, M | 1 |
| Chau, I; Smyth, EC; Tarazona, N | 1 |
| Akiyama, K; Alam, MT; Hida, K; Hida, Y; Kawamoto, T; Maishi, N; Ohba, Y; Ohga, N; Ohmura, H; Shindoh, M; Torii, C; Yamada, K | 1 |
| Han, J; Hou, G; Kong, Y; Nie, P; Sun, H; Yang, G | 1 |
| Chen, HZ; Dong, X; Fang, C; Gao, YG; Guan, YY; Liu, HJ; Liu, YR; Lu, Q; Luan, X; Wang, C; Yang, SC | 1 |
| Aslan, B; Calin, G; Dalton, HJ; Del C Monroig, P; Fernandez-de Thomas, RJ; Fuentes-Mattei, E; Gonzalez-Villasana, V; Ivan, C; Kahraman, N; Kanlikilicer, P; Lopez-Berestein, G; Ozpolat, B; Pradeep, S; Previs, RA; Rodriguez-Aguayo, C; Sood, AK; Velazquez-Torres, G; Wang, H | 1 |
| Ancukiewicz, M; Duda, DG; Engelman, JA; Fidias, P; Gandhi, L; Heist, RS; Jain, RK; Lynch, TJ; Neal, JW; Pennell, NA; Sahani, DV; Sequist, LV; Shaw, AT; Temel, JS | 1 |
| Hiura, K; Iwaki-Egawa, S; Komori, H; Shiraishi, A; Suzuki, C; Takamura, K; Watanabe, Y; Yamamoto, M | 1 |
| Guo, P; Li, Z; Pan, W; Song, S; Tian, Y; Yang, X; Zheng, J | 1 |
| Alishekevitz, D; Apte, RN; Benhar, M; Fremder, E; Isakov, E; Kaneti, L; Kaplanov, I; Machluf, M; Miller, V; Shaked, Y; Voloshin, T; Voronov, E | 1 |
| Ann, DK; Arif, M; Chen, CH; Cheng, CT; Fong, LW; Wu, R; Yuan, Y; Zhai, J | 1 |
| Chen, HZ; Fang, C; Gao, YG; Liu, HJ; Liu, YR; Luan, X; Wu, H; Yu, DH | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Gao, H; He, Q; Liu, Y; Mei, L; Qiu, Y; Shi, K; Xu, C; Yang, Y; Yu, Q; Zhang, Q; Zhang, Z | 1 |
| Gao, X; Gong, C; Huang, N; Men, K; Shi, H; Wang, B; Wei, X; Wei, Y; Wu, Q; Zheng, F | 1 |
| Armaiz-Pena, GN; Coleman, RL; Dalton, HJ; Davis, AN; Hansen, JM; Langley, RR; Lin, YG; Merritt, WM; Nick, AM; Pradeep, S; Previs, RA; Sood, AK | 1 |
| Choe, J; Han, M; Jeoung, D; Kim, H; Kim, Y; Kim, YM; Lee, H; Lee, YS; Park, D | 1 |
| Castelo, B; Díaz, E; Espinosa, E; Fresno, JÁ; Gámez, A; Hardisson, D; Heredia, V; Herranz, J; Martínez-Marin, V; Mendiola, M; Miguel, M; Pinto, Á; Ramírez de Molina, A; Redondo, A; Yébenes, L; Zamora, P | 1 |
| Bach, BA; Bamias, A; Brize, A; Coleman, RL; DeCensi, A; Fabbro, M; Fujiwara, K; Lhommé, C; Monk, BJ; Oaknin, A; Provencher, D; Raspagliesi, F; Ray-Coquard, I; Vergote, I; Vogl, FD; Zhang, K | 1 |
| Bandyopadhyay, AK; Banerjee, I; Chattopadhyay, S; De, K; Dey, G; Ganguly, S; Gupta, A; Mandal, M; Misra, M; Mukherjee, D; Mukherjee, M | 1 |
| Chen, HZ; Dong, X; Fang, C; Gao, YG; Guan, YY; Liu, HJ; Liu, YR; Lovell, JF; Lu, Q; Luan, X; Sun, P; Yang, SC; Zhao, M; Zheng, L | 1 |
| Backen, A; Banks, RE; Berzuini, C; Clamp, A; Dive, C; Jayson, GC; Kaplan, R; Kristensen, GB; Pujade-Lauraine, E; Renehan, A; Scherer, SJ; Zhou, C | 1 |
| Bateman, S; Heise, C; Hidalgo, M; Hou, S; Maitra, A; Pai, SG; Pierce, DW; Rajeshkumar, NV; Tong, Z; Von Hoff, DD; Yabuuchi, S | 1 |
| Chen, Z; Du, F; He, D; Jin, J; Li, H; Lu, H; Ma, X; Pan, Q; Tang, C; Wang, Y; Yao, X; Zang, X; Zhang, P | 1 |
| Dou, Y; Sun, R; Tian, Z; Wei, H; Yue, T; Zheng, X | 1 |
| Hu, Y; Jiang, T; Lu, H; Mei, H; Pang, Z; Shi, W; Wang, L; Zhang, B | 1 |
| Chen, C; Huang, Z; Li, X; Su, F; Zhang, M | 1 |
| Chen, Y; Gong, D; He, G; He, L; Jin, Q; Li, S; Song, X; Tan, X; Wu, J; Xu, B; Yang, L; Yu, T; Zeng, J | 1 |
| Chen, J; Feng, J; Gao, X; Jiang, T; Kang, T; Wei, D; Wei, X; Yao, J; Zhu, Q | 1 |
| Byakhov, M; Daeyaert, F; Gavrilova, E; Harrison, D; Joos, JB; Kochenkov, D; Peretolchina, N; Solomko, E; Stepanova, E; Tjulandin, S; Tsimafeyeu, I; Tyulyandina, A; Van Aken, K; Yin, W | 1 |
| An, HJ; Heo, JH; Jeong, JY; Jung, SG; Kang, H; Kim, G; Kim, S; Kim, TH; Kwon, AY | 1 |
| Berghaus, A; Dellian, M; Eichhorn, ME; Michaelis, U; Sauer, B; Strieth, S; Teifel, M; Werner, A | 1 |
| Anthony, CT; Lyons, JM; Thomson, JL; Woltering, EA | 1 |
| Collinson, F; Jayson, G | 1 |
| Banik, NL; George, J; Ray, SK | 1 |
| Gilbert, BE; Kline, K; Latimer, P; Menchaca, M; Sanders, BG; Snyder, RM; Yu, W | 1 |
| Alì, G; Allegrini, G; Barletta, MT; Bocci, G; Bona, E; Coltelli, L; Danesi, R; Del Tacca, M; Falcone, A; Fioravanti, A; Fontanini, G; Giuntini, N; Orlandi, P | 1 |
| Bohnenkamp, H; Bruns, CJ; Dellian, M; Eichhorn, ME; Guenzi, E; Ischenko, I; Jauch, KW; Luedemann, S; Michaelis, U; Papyan, A; Preissler, G; Strieth, S; Werner, A | 1 |
| Aruga, T; Kuroi, K; Matsumoto, G; Muta, M; Nakashima, E; Sai, Y; Saji, S; Suzuki, E; Toi, M; Yanagawa, T | 1 |
| Krylov, AL | 1 |
| DiGiacomo, V; Granot, T; Levin, B; Meruelo, D; Tseng, JC | 1 |
| Berndt, A; Cesca, M; D'Incalci, M; Frapolli, R; Giavazzi, R; Kosmehl, H; Richter, P; Ryan, AJ; Scarlato, V | 1 |
| Jiang, H; Kanwar, JR; Pan, S; Sun, X; Tao, W; Zhang, M | 1 |
| Allen, JK; Armaiz-Pena, GN; Coleman, RL; Jaffe, RB; Jennings, NB; Landen, CN; Lin, YG; Lu, C; Mangala, LS; Moreno-Smith, M; Nick, AM; Schmandt, R; Shahzad, MM; Sood, AK; Stone, RL | 1 |
| Chen, HZ; Fang, C; Lu, Q; Xie, J; Yu, DH | 1 |
| Chang, MC; Chen, CA; Chen, YL; Cheng, WF; Chiang, YC; Ho, CM; Hsieh, CY; Sun, WZ; Syu, MH | 1 |
| Ho, PC; Wang, Z | 1 |
| Bagnato, A; Cianfrocca, R; Di Castro, V; Natali, PG; Rosanò, L; Spinella, F | 1 |
| Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P | 1 |
| Figg, WD; Gardner, ER; Kelly, M; Lee, KJ; Li, H; Moore, W; Springman, E | 1 |
| Devineni, S; Ghebre, R; Ghosh, G; Jing, Y; Joshi, HP; Ramakrishnan, S; Subramanian, IV; Truskinovsky, AM | 1 |
| Dafni, H; Hu, S; Larson, PE; Ronen, SM; Venkatesh, HS; Vigneron, DB; Wang, C; Ward, CS; Yoshihara, HA; Zhang, X | 1 |
| Cheng, L; Hu, S; Huang, H; Ling, B; Liu, J; Shen, G; Song, L; Wei, W; Wu, Q; Xiao, W; Zhang, A; Zhao, T | 1 |
| Chang, JS; Chen, CA; Chen, MW; Hsiao, M; Hsiao, SM; Kuo, ML; Lai, TC; Lo, CW; Rose-John, S; Wang, S; Wei, LH | 1 |
| Eldar-Boock, A; Lupu, R; Miller, K; Sanchis, J; Satchi-Fainaro, R; Vicent, MJ | 1 |
| Bai, C; Gu, A; Guo, S; Han, B; Jiang, L; Jin, X; Liu, W; Luo, Y; Shen, J; Wang, H; Xiu, Q; Zhang, Y; Zhao, Y; Zhou, J; Zhuang, Z | 1 |
| Donahue, RN; McLaughlin, PJ; Zagon, IS | 1 |
| Benayoun, L; Bril, R; Gingis-Velitski, S; Kerbel, RS; Man, S; Milsom, C; Munster, M; Shaked, Y; Voloshin, T | 1 |
| Gupta, R; Krissansen, GW; Kuhn-Sherlock, B; Macgibbon, AK; Sun, X; Zhang, J | 1 |
| Fukami, T; Hikita, S; Kondo, H; Kuroki, M; Miyamoto, S; Takahashi, Y; Tsujioka, H; Ueda, T; Yotsumoto, F | 1 |
| Bryant, A; Gaitskell, K; Kehoe, S; Martinek, I; Morrison, J; Nicum, S | 1 |
| Feenstra, K; Huang, Y; Jiang, W; Qian, CN; Resau, JH; Xue, C; Zhang, L; Zhao, HY; Zhao, YY | 1 |
| Chen, S; Huang, Y; Luo, LM; Song, P; Wang, X; Yu, KF; Zhang, Q; Zhang, X; Zhao, BX; Zhao, Y | 1 |
| Alessandri, G; Arnaldo, C; Bonomi, A; Cappelletti, G; Cartelli, D; Cavicchini, L; Ciusani, E; Coccè, V; Falchetti, ML; Ferrari, M; Invernici, G; Locatelli, A; Marfia, G; Navone, S; Pallini, R; Parati, E; Pessina, A; Sisto, F; Viganò, L | 1 |
| Bekele, BN; Biernacka, A; Erez, B; Herbst, RS; Hosho, K; Jacoby, JJ; Jürgensmeier, JM; Komaki, R; Korshunova, MV; O'Reilly, MS; Ryan, A; Smith, PD; Takahashi, O; Wistuba, II | 1 |
| Breen, S; Chang, Y; Coats, S; Coffman, K; Czapiga, M; Fazenbaker, C; Gingles, N; Inigo, I; Jallal, B; Lavallee, T; Leow, CC; Peterson, N; Ricketts, SA; Soukharev, S; Woods, R | 1 |
| Alitalo, K; Anttila, M; Hamalainen, K; Heinonen, S; Koponen, JK; Kosma, VM; Laidinen, S; Laurema, A; Sallinen, H; Sopo, M; Tuppurainen, L; Tuunanen, P; Yla-Herttuala, S | 1 |
| Bookman, MA | 1 |
| Chia, S; Lohmann, AE | 1 |
| Dai, W; Li, RT; Liang, L; Lin, SW; Lu, JK; Xiang, Y; Yang, TY; Zhang, Q; Zhang, Y | 1 |
| Carugati, E; Neri, D; Pasche, N; Pretto, F; Wulhfard, S | 1 |
| Ali, A; Anbalagan, M; Bu, Y; Carrier, L; Hangauer, D; Jones, RK; Marsden, CG; Rowan, BG; Sheng, M | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Collinson, FJ; Perren, TJ; Seligmann, J | 1 |
| Hall, KL; Rajput, S; Ran, S; Volk-Draper, LD; Wilber, A | 1 |
| Abe, S; Araki, T; Fushimi, A; Higaki, K; Ishikawa, K; Kimura, T; Molema, G; Ogawara, K; Yoshizawa, Y | 1 |
| Bhowmick, NA; Billet, S; Das, S; Fernandez, A; Fisher, PB; Kitada, S; Mitra, S; Noberini, R; Pasquale, EB; Pellecchia, M; Stebbins, JL; Wang, S; Wu, B; Zhang, Z | 1 |
| Cronin, EB; DeFusco, PA; Hart, J; Hegde, PU; Kane, M; Ricci, A; Tannenbaum, SH; Tavakoli, B; Xu, Y; Zhu, Q | 1 |
| Alessandri, G; Benetti, A; Bonomi, A; Caruso, A; Cavicchini, L; Ceccarelli, P; Ciusani, E; Coccè, V; Crovace, A; Falchetti, ML; Ferrari, M; Marfia, G; Navone, S; Parati, E; Pascucci, L; Pessina, A; Sisto, F; Zicari, S | 1 |
| Bombardelli, E; Cassinelli, G; Cuccuru, G; Laccabue, D; Lanzi, C; Pratesi, G; Supino, R; Zuco, V; Zunino, F | 1 |
| Alvarez, E; Faul, MM; Menon, K; Shih, C; Teicher, BA | 1 |
| Baker, CH; Bucana, CD; Fidler, IJ; Kedar, D; McCarty, MF; Tsan, R; Weber, KL | 1 |
| Agus, DB; Cordon-Cardo, C; Drobnjak, M; Fox, WD; Higgins, B; Maiese, KM; Scher, HI | 1 |
| Bagnato, A; Cirilli, A; Muller, A; Natali, PG; Nicotra, MR; Salani, D; Simeone, P; Venuti, A | 1 |
| Ashton, AW; Hotchkiss, KA; Mahmood, R; Russell, RG; Schwartz, EL; Sparano, JA | 1 |
| Barrett, M; Burnitz, MC; Dipierro, C; Eto, M; Gibson, JJ; Myers, C; Phelps, C; Read, P; Somlyo, AP; Somlyo, AV | 1 |
| Chikazawa, M; Fukata, S; Inoue, K; Shuin, T; Yoshikawa, C | 1 |
| Kunstfeld, R; Michaelis, U; Naujoks, K; Petzelbauer, P; Teifel, M; Umek, W; Wickenhauser, G; Wolff, K | 1 |
| Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Salani, D; Spinella, F; Venuti, A | 1 |
| Cao, Y; Han, R; Liu, HY; Wang, F; Xu, SF | 1 |
| Dicker, AP; Grant, DS; Iliakis, G; Williams, TL | 1 |
| Herbst, RS; Khuri, FR | 1 |
| Klos, KS; Lee, S; Nagata, Y; Yang, W; Yu, D; Zhang, L; Zhou, X | 1 |
| Dhar, DK; Fujiwaki, R; Hata, K; Ito, H; Miyazaki, K; Nagasue, N; Nakayama, K; Osaki, M | 1 |
| Cao, Y; Fu, Z; Han, R; Liu, H; Wang, F; Zhao, W | 1 |
| Bower, M; Gazzard, BG; Gotch, F; Hewitt, P; Mandalia, S; Nelson, M; Patterson, S; Portsmouth, S; Powles, T; Stebbing, J; Thirlwell, C; Wildfire, A | 1 |
| Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Ki Hong, W; O'Reilly, MS; Onn, A; Wu, W | 1 |
| Figg, WD; Ng, SS; Sparreboom, A | 1 |
| Dahut, WL; Figg, WD; Retter, AS | 1 |
| Dellian, M; Eichhorn, ME; Michaelis, U; Sauer, B; Schulze, B; Strieth, S; Teifel, M | 1 |
| Albertsson, P; Damber, JE; Lennernäs, B; Norrby, K | 1 |
| Brandwijk, RJ; Dings, RP; Griffioen, AW; Thijssen, VL | 1 |
| Bubley, GJ; He, X; Jayaram, DR; Merchan, JR; Sukhatme, VP; Supko, JG | 1 |
| Gandara, D; Guo, L; Lau, D; Xue, L; Young, LJ | 1 |
| Braguer, D; Briand, C; Camoin, L; Carré, M; Pasquier, E; Pourroy, B; Rebaï, O | 1 |
| Carus, AP; Ferrero, A; Fuso, L; Jacomuzzi, ME; Mazzola, S; Ravarino, N; Sarotto, I; Sismondi, P; Spanu, PG; Zola, P | 1 |
| Fidler, IJ; Kim, SJ; Lev, DC; Nam, DH; Onn, A; Price, JE; Stone, V; Yazici, S | 1 |
| Atherton, JA; Baker, DA; Barth, W; Cohen, BD; Cooper, B; Dalvie, D; Hungerford, W; Kath, JC; Lin, J; Lyssikatos, JP; Moraski, G; Pollack, V; Ralston, S; Roberts, WG; Savage, D; Soderstrom, C; Soderstrom, E; Szewc, R; Tkalcevic, G; Ung, E; Wang, HF; Whalen, PM | 1 |
| Braguer, D; Briand, C; Honore, S; Jordan, MA; Lehmann, M; Pasquier, E; Pourroy, B | 1 |
| Grossman, A; Horwitz, SB; Keller, S; Lia, M; Lopez-Barcons, L; McDaid, HM; Pérez-Soler, R | 1 |
| Bagnato, A; Di Castro, V; Natali, PG; Rosanò, L; Spinella, F | 1 |
| Lamph, WW; Yen, WC | 1 |
| Bekele, BN; Bucana, CD; Fidler, IJ; Hawthorne, VS; Jasser, SA; Kim, SJ; Mandal, M; Myers, JN; Park, YW; Yazici, YD; Yigitbasi, OG; Younes, MN | 1 |
| Busby, JE; Fan, D; Fidler, IJ; He, J; Kim, SJ; Thaker, P; Yazici, S; Yokoi, K | 1 |
| Fujiwara, M; Hibi, K; Kodera, Y; Koike, M; Nakanishi, H; Nakao, A; Ohashi, N; Tatematsu, M; Yokoyama, H | 1 |
| Corcoran, NM; Costello, AJ | 1 |
| Gradishar, WJ | 1 |
| Dong, C; Goldschmidt-Clermont, PJ; Hummers, L; Liu, X; Wang, T; Wigley, FM; Zhu, S | 1 |
| Amino, N; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M | 1 |
| Hattori, H; Hayashi, T; Ishihara, M; Ishizuka, T; Kikuchi, M; Maehara, T; Matsui, T; Nakamura, S; Obara, K; Ozeki, Y; Saito, Y; Takase, B; Yura, H | 1 |
| Burt, HM; Gleave, J; Gleave, ME; Jackson, JK | 1 |
| Liu, ZS; Sun, Q; Zhang, ZL | 1 |
| Becker, S; Brix, G; Dellian, M; Eichhorn, ME; Griebel, J; Jauch, KW; Michaelis, U; Ruhstorfer, H; Sauer, B; Strieth, S; Teifel, M; Werner, A | 1 |
| Schuch, G | 1 |
| Ishiguro, Y; Kawakami, M; Matsuda, H; Nishimura, G; Sano, D; Tsukuda, M | 1 |
| Freeze, BS; Goldberg, GL; Horwitz, SB; Huang, GS; Lopez-Barcons, L; McDaid, HM; Smith, AB | 1 |
| Amino, N; Hisamichi, H; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M | 1 |
| Bani, MR; Borsotti, P; Cassis, L; Eccles, SA; Garofalo, A; Giavazzi, R; Naumova, E; Riccardi, E; Scanziani, E; Ubezio, P | 1 |
| Bouma-ter Steege, JC; Castermans, K; Dings, RP; Dirkx, AE; Griffioen, AW; Kwee, L; Mayo, KH; oude Egbrink, MG; Thijssen, VL; van der Schaft, DW; Wagstaff, J | 1 |
| Fujita, M; Hattori, H; Ishihara, M; Kanatani, Y; Kikuchi, M; Maehara, T; Masuoka, K; Morimoto, Y; Nakamura, S; Obara, K; Takase, B | 1 |
| Busby, JE; Do, KA; Fan, D; Fidler, IJ; He, J; Kim, SJ; Logothetis, C; Mathew, P; Maya, M; Nakamura, T; Uehara, H; Wang, X; Yazici, S | 1 |
| Desai, N; Figg, WD; Kerbel, RS; Lee, C; Man, S; Ng, SS; Shaked, Y; Soon-Shiong, P; Sparreboom, A | 1 |
| McGuire, WP | 1 |
| Hou, M; Qiu, M; Yi, C | 1 |
| Bonnar, J; D'Arcy, T; Laios, A; McGuinness, EP; O'Leary, JJ; O'Toole, SA; Sheppard, BL | 1 |
| Baeuerle, PA; Clark, D; Freimark, B; Nickel, J; Pernasetti, F; Van Epps, D | 1 |
| Burstein, HJ; Rugo, HS; Sledge, GW | 1 |
| Herbst, R; Sandler, A; Vokes, E | 1 |
| Isner, JM; Kirchmair, R; Kusano, K; Losordo, DW; Panagiotou, E; Ropper, AH; Schratzberger, P; Silver, M; Tietz, AB; Walter, DH; Weber, A; Weinberg, DH; Yoon, YS | 1 |
| Bensussan, A; Bizzini, B; Gallo, RC; Genne, P; Larcier, P; Le Buanec, H; Paturance, S; Rad, FH; Ryffel, B; Uzan, G; Zagury, D | 1 |
| Horiguchi, Y; Kikuchi, E; Kosaka, T; Kosugi, M; Miyajima, A; Murai, M | 1 |
| Fujita, K; Ishiguro, Y; Kawakami, M; Kimura, M; Matsuda, H; Nishimura, G; Sano, D; Tsukuda, M; Yamashita, Y | 1 |
| Feng, L; Garcia, GE; Jing, N; Mao, L; Weerasinghe, P; Yuan, P; Zhu, Q | 1 |
| Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Spinella, F | 1 |
| Dong, X; Jiang, H; Jiang, X; Krissansen, GW; Li, J; Sun, X; Xu, Z | 1 |
| Bonezzi, K; Frapolli, R; Giavazzi, R; Kuhn, E; Martinelli, M; Riccardi, E; Ryan, AJ; Taraboletti, G; Zucchetti, M | 1 |
| Han, ES; Monk, BJ | 1 |
| Bai, CQ; Guo, HL; Song, YF; Wang, DT | 1 |
| Marty, M; Pivot, X | 1 |
| Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Krishnamurthi, S; Ness, A; Nock, C; Remick, SC; Sanborn, SL | 1 |
| DeSesso, JM; Goeringer, GC; Scialli, AR | 1 |
| Banquerigo, ML; Brahn, E; Oliver, SJ | 1 |
| Arsenault, AL; Bains, SK; Burt, HM; Hunter, WL; Jackson, JK; Liggins, RT; Oktaba, AM | 1 |
| Arsenault, LA; Burt, HM; Dordunoo, SK; Hunter, WL; Jackson, JK; Oktaba, AM | 1 |
| Markman, M | 1 |
| Herbst, RS; Takeuchi, H; Teicher, BA | 1 |
| Arsenault, AL; Banquerigo, ML; Brahn, E; Hunter, WL; Lhoták, S | 1 |
| Belotti, D; Borsotti, P; Drudis, T; Giavazzi, R; Pitelli, MR; Taraboletti, G; Vergani, V; Viale, G | 1 |
| Bynon, S; Eckoff, D; Placidi, L; Scott, EC; Sommadossi, JP | 1 |
| Appelt, K; Bloom, LA; Brekken, J; McDermott, CD; Shalinsky, DR; Varki, NM; Zook, S; Zou, H | 1 |
| Hunter, NR; Mason, KA; Milas, L; Schimming, R | 1 |
| Bianco, AR; Bianco, R; Ciardiello, F; Damiano, V; De Placido, S; Fontanini, G; Tortora, G | 1 |
| Davis, DW; Dinney, CP; Hicklin, DJ; Inoue, K; Karashima, T; McConkey, DJ; Radinsky, R; Slaton, JW | 1 |
| Albanese, C; Amanatullah, DF; Hulit, J; Lisanti, MP; Pestell, RG; Reutens, A; Rosen, E; Sparano, JA; Wang, C; Zafonte, BT | 1 |
| Bruns, CJ; Davis, DW; Dinney, CP; Hicklin, DJ; Inoue, K; McConkey, DJ; Perrotte, P; Radinsky, R; Slaton, JW; Sweeney, P | 1 |
| Hong, SD; Hong, SP; Kim, MJ; Kim, YY; Myoung, H | 1 |
| Martin, C; Pan, J; Xu, G; Yeung, SC | 1 |
| Fountzilas, G; Giatromanolaki, A; Kittas, C; Koukourakis, MI; Rigatos, S; Sivridis, E; Stathopoulos, GP; Vrettou, E | 1 |
| Bauer, KS; Bostick-Bruton, F; Figg, WD; Fuse, E; Goldspiel, B; Kohn, EC; Kulpa, V; Liotta, LA; Minasian, L; Noone, M; Pluda, J; Reed, E; Sarosy, GA; Tompkins, A | 1 |
| Chen, GA; Lorang, D; Nguyen, DM; Schrump, DS; Stewart, JH; Tabibi, E | 1 |
| Dinney, CP; Inoue, K; Izawa, J; Karashima, T; Kedar, D; Kim, SJ; McConkey, DJ; Millikan, R; Perrotte, P; Shuin, T; Slaton, JW; Sweeney, P; Yoshikawa, C | 1 |
| Favaudon, V; Hennequin, C | 1 |
| Agata, N; Bamberg, M; Dickerson, WM; Fram, R; Kalluri, R; Kamphaus, GD; Kharbanda, S; Kufe, D; Milhollen, M; Reimer, CL; Rook, SL; Tammam, JG | 1 |
| Blanchard, JM | 1 |
| Baccarini, S; Bacigalupo, I; Barillari, G; Bugarini, R; Bussolino, F; Cafaro, A; Carlei, D; Ensoli, B; Falchi, M; Leone, P; Malavasi, L; Monini, P; Palladino, C; Rezza, G; Sgadari, C; Toschi, E; Valdembri, D | 1 |
| Burke, P; Gandour-Edwards, R; Guo, L; Lau, D; Lo, SH | 1 |
| Douillard, JY | 1 |
| Dinney, CP; Fan, Z; Hicklin, DJ; Izawa, JI; Karashima, T; Kedar, D; Kim, SJ; Pettaway, C; Shuin, T; Slaton, JW; Sweeney, P | 1 |
| Abbruzzes, J; Azhdarinia, A; Bryant, JL; Fogler, WE; Herbst, R; Kalimi, SK; Kim, EE; Kim, KD; Ozaki, K; Podoloff, DA; Roach, JS; Schechter, NR; Wu, P; Yang, DJ; Yu, DF | 1 |
| Larsson, LI; Lichtenberg, J | 1 |
| Bengtsson, NO; Blomqvist, C; Heikkilä, R; Malmström, P; Ostenstad, B; Paavonen, T; Saksela, E; Sjöström, J; Tynninen, O; Valvere, V; von Boguslawski, K; Wist, E | 1 |
20 review(s) available for paclitaxel and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Antiangiogenic therapies in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel | 2018 |
Nintedanib for Advanced Epithelial Ovarian Cancer: A Change of Perspective? Summary of Evidence from a Systematic Review.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Female; Humans; Indoles; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel | 2019 |
Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Indoles; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2014 |
Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Approval; Humans; Hypertension; Immunotherapy; Neovascularization, Pathologic; Neutropenia; Paclitaxel; Ramucirumab; Randomized Controlled Trials as Topic; Stomach Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
New therapeutic agents in ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Drug Administration Routes; ErbB Receptors; Female; Humans; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly Adenosine Diphosphate Ribose; Protein Kinase Inhibitors; Proteins; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2009 |
[Experience in using stents with an antiproliferative coating in treatment of stenoses and occlusions of coronary arteries. Review of the literature].
Topics: Coronary Stenosis; Coronary Vessels; Drug-Eluting Stents; Humans; Immunosuppressive Agents; Neovascularization, Pathologic; Paclitaxel; Prosthesis Design; Sirolimus; Treatment Outcome | 2008 |
Angiogenesis inhibitors for the treatment of ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Female; Humans; Indoles; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Recombinant Fusion Proteins; Survival Analysis | 2011 |
First-line chemotherapy in epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A | 2012 |
Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cardiotoxins; Disease-Free Survival; Female; Humans; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A | 2012 |
Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Meta-Analysis as Topic; Neoadjuvant Therapy; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel | 2012 |
Mode of action of docetaxel - a basis for combination with novel anticancer agents.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Follow-Up Studies; Humans; Male; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Pharmacogenetics; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer.
Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Cyclohexanes; Humans; Male; Minocycline; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Prostatic Neoplasms; Sesquiterpenes | 2003 |
Chitosan hydrogel as a drug delivery carrier to control angiogenesis.
Topics: Animals; Biocompatible Materials; Chitosan; Cross-Linking Reagents; Drug Delivery Systems; Fibroblast Growth Factor 2; Hydrogels; Mice; Mice, Inbred Strains; Neovascularization, Pathologic; Occlusive Dressings; Paclitaxel; Rabbits; Ultraviolet Rays; Wound Healing | 2006 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Multicenter Studies as Topic; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Angiogenesis inhibition in the treatment of lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Bevacizumab in the treatment of ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Female; Hematologic Diseases; Humans; Intestinal Perforation; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Salvage Therapy; Vascular Endothelial Growth Factor A | 2007 |
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Taxoids; Vascular Endothelial Growth Factor A | 2008 |
Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Databases, Factual; Enzyme Inhibitors; Flavonoids; Humans; Microtubule-Associated Proteins; Neovascularization, Pathologic; Oncogenes; Paclitaxel; Piperidines; Receptors, Estrogen; Tamoxifen; Transforming Growth Factor beta; Trastuzumab; Tumor Suppressor Proteins | 2000 |
[Molecular mechanisms of oncogenic transformation: what's new?].
Topics: Animals; Antineoplastic Agents, Phytogenic; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Disease Progression; Drug Resistance; Fusion Proteins, bcr-abl; Humans; Mice; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Neural Cell Adhesion Molecules; Paclitaxel; Protein Serine-Threonine Kinases; Radiation Tolerance; Rats; Thrombospondins; Transforming Growth Factor beta; Tuberous Sclerosis | 2002 |
[New prospects in the treatment of non-small-cell lung carcinoma (NSCLC): new biological factors].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Lung Neoplasms; Metalloendopeptidases; Neovascularization, Pathologic; Organic Chemicals; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Research; Time Factors | 2001 |
10 trial(s) available for paclitaxel and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Topics: Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A | 2015 |
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Placebo Effect; Quality of Life; Recombinant Fusion Proteins; Treatment Outcome | 2016 |
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.
Topics: Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bevacizumab; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Humans; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Receptor, TIE-2 | 2016 |
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Endostatins; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Recombinant Proteins; Treatment Outcome | 2011 |
Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anthracyclines; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Biomarkers, Tumor; Disease Progression; Female; Fibroblast Growth Factor 2; Humans; Interleukin-6; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Sarcoma, Kaposi; Skin Neoplasms; Time Factors; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2003 |
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Collagen; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Humans; In Vitro Techniques; Isoenzymes; Laminin; Lung; Male; Melanoma; Membrane Proteins; Neovascularization, Pathologic; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proteoglycans; Pyrazoles; Skin; Skin Neoplasms; Sulfonamides; Time Factors; Tumor Cells, Cultured; Umbilical Veins | 2005 |
In focus: non-small cell lung cancer: E1505.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Humans; Lung Neoplasms; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A | 2007 |
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Thalidomide | 2008 |
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Middle Aged; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Recurrence; Time Factors; Treatment Outcome; Triazoles; Tumor Cells, Cultured | 2001 |
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neovascularization, Pathologic; Paclitaxel; Prognosis; Taxoids; Time Factors; Treatment Outcome | 2002 |
209 other study(ies) available for paclitaxel and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microtubules; Molecular Docking Simulation; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship | 2017 |
Selective and Marked Blockade of Endothelial Sprouting Behavior Using Paclitaxel and Related Pharmacologic Agents.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Cells, Cultured; Docetaxel; Endothelial Cells; Endothelium, Vascular; Epothilones; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred C57BL; Morphogenesis; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel | 2021 |
Rosmarinic acid suppresses inflammation, angiogenesis, and improves paclitaxel induced apoptosis in a breast cancer model via NF3 κB-p53-caspase-3 pathways modulation.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Cinnamates; Depsides; Inflammation; Mice; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Paclitaxel; Rosmarinic Acid; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2021 |
Acquisition of paclitaxel resistance modulates the biological traits of gastric cancer AGS cells and facilitates epithelial to mesenchymal transition and angiogenesis.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Neovascularization, Pathologic; Paclitaxel; Stomach Neoplasms | 2022 |
YAP inhibitor verteporfin suppresses tumor angiogenesis and overcomes chemoresistance in esophageal squamous cell carcinoma.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neovascularization, Pathologic; Paclitaxel; Verteporfin | 2023 |
JP1 normalizes tumor vasculature to suppress metastasis and facilitate drug delivery by inhibiting IL-8.
Topics: Humans; Interleukin-8; Neoplasms; Neovascularization, Pathologic; Oxygen; Paclitaxel; Tumor Microenvironment | 2023 |
Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Female; Heterocyclic Compounds, 3-Ring; Humans; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Triple Negative Breast Neoplasms; Wnt Signaling Pathway | 2019 |
Preparation of Cholera Toxin Subunit B Functionalized Nanoparticles for Targeted Therapy of Glioblastoma.
Topics: Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Cholera Toxin; Drug Carriers; Glioblastoma; Glycosphingolipids; Microscopy, Electron, Transmission; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer | 2020 |
Anticancer effects of NSC‑631570 (Ukrain) in head and neck cancer cells: In vitro analysis of growth, invasion, angiogenesis and gene expression.
Topics: Antineoplastic Agents; Berberine Alkaloids; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Paclitaxel; Phenanthridines | 2020 |
Effect of low dose metronomic therapy on MCF-7 tumor cells growth and angiogenesis. Role of muscarinic acetylcholine receptors.
Topics: Administration, Metronomic; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbachol; Cell Line; Cell Proliferation; Cell Survival; Cholinergic Agonists; Drug Interactions; Female; Humans; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Receptors, Muscarinic | 2020 |
Chemotherapy-Induced IL8 Upregulates MDR1/ABCB1 in Tumor Blood Vessels and Results in Unfavorable Outcome.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Induction Chemotherapy; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Prognosis; Survival Rate; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2020 |
The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Arecoline; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbachol; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholinergic Agonists; Down-Regulation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Neovascularization, Pathologic; Paclitaxel; Receptor, Muscarinic M2; RNA, Small Interfering; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2020 |
B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; B7 Antigens; Biomarkers, Tumor; Drug Delivery Systems; Female; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; RAW 264.7 Cells; Triple Negative Breast Neoplasms; Tumor Microenvironment; Tumor-Associated Macrophages | 2021 |
Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cancer-Associated Fibroblasts; Cell Line, Tumor; Doxorubicin; Endothelial Cells; Female; Humans; Hypoxia; Integrin alphaVbeta3; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Protein-Lysine 6-Oxidase; Signal Transduction; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Additional alkaloids from Zoanthus vietnamensis with neuroprotective and anti-angiogenic effects.
Topics: Alkaloids; Animals; Anthozoa; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Discovery; Ganglia, Spinal; Humans; Mice; Molecular Structure; Neovascularization, Pathologic; Neurons; Paclitaxel; Stem Cells | 2021 |
Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.
Topics: Angiopoietin-2; Animals; Biglycan; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Fibrosis; Humans; Mice; Mice, Knockout; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Prognosis; Signal Transduction; Stromal Cells; Treatment Outcome; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2021 |
Paclitaxel-loaded polymeric nanoparticles based on α-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma:
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Carriers; Female; Head and Neck Neoplasms; Mice; Mice, Nude; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Polymers; Squamous Cell Carcinoma of Head and Neck; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Endothelial Cells; Fluorouracil; Humans; Neovascularization, Pathologic; Paclitaxel; Stomach Neoplasms; Thalidomide; Thymidine Phosphorylase; Up-Regulation | 2021 |
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biphenyl Compounds; Cell Proliferation; Coculture Techniques; Endothelial Cells; Female; Gene Silencing; Hedgehog Proteins; Human Umbilical Vein Endothelial Cells; Humans; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Pyridines; RNA, Messenger; Signal Transduction; Thrombospondin 1; Tissue Array Analysis; Transfection; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult; Zinc Finger Protein GLI1 | 2017 |
Taxol alleviates collagen-induced arthritis in mice by inhibiting the formation of microvessels.
Topics: Animals; Arthritis, Experimental; Disease Models, Animal; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Paclitaxel; Synovial Membrane; Vascular Endothelial Growth Factor A | 2019 |
Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice.
Topics: A549 Cells; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents, Phytogenic; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; Drug Delivery Systems; Drug Synergism; Drug Therapy, Combination; Gene Expression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Micelles; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Polyesters; Polyethylene Glycols; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.
Topics: Albumins; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |
Tumor associated macrophages and angiogenesis dual-recognizable nanoparticles for enhanced cancer chemotherapy.
Topics: Animals; Annexin A1; Antineoplastic Agents; Cell Proliferation; Colonic Neoplasms; Drug Delivery Systems; Humans; Macrophages; Mice; Mice, Nude; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Peptide Fragments; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Caseins; Cell Line, Tumor; Drug Liberation; Female; Hyaluronic Acid; Hydroxamic Acids; Mammary Neoplasms, Experimental; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Nanoconjugates; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Prodrugs; Protein Binding | 2018 |
Cripto-1 promotes resistance to drug-induced apoptosis by activating the TAK-1/NF-κB/survivin signaling pathway.
Topics: Apoptosis; Carcinogenesis; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Drug Resistance, Neoplasm; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; GPI-Linked Proteins; HEK293 Cells; Humans; Inhibitor of Apoptosis Proteins; Intercellular Signaling Peptides and Proteins; MAP Kinase Kinase Kinases; Neoplasm Proteins; Neovascularization, Pathologic; NF-kappa B; Paclitaxel; Signal Transduction; Survivin | 2018 |
Sequential delivery of VEGF siRNA and paclitaxel for PVN destruction, anti-angiogenesis, and tumor cell apoptosis procedurally via a multi-functional polymer micelle.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Drug Delivery Systems; Female; Gene Transfer Techniques; Human Umbilical Vein Endothelial Cells; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Micelles; Neovascularization, Pathologic; Paclitaxel; Polyesters; Polyethylene Glycols; RNA, Small Interfering; RNAi Therapeutics; Vascular Endothelial Growth Factor A | 2018 |
Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Clinical Decision-Making; Cytoreduction Surgical Procedures; Female; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasms, Cystic, Mucinous, and Serous; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; ROC Curve; Transcriptome | 2018 |
PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Peptides; Programmed Cell Death 1 Receptor; Regional Blood Flow; Survival Analysis; Tissue Distribution | 2018 |
Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line; Disease Models, Animal; Endothelium, Lymphatic; Female; Humans; Immunohistochemistry; Lymph Nodes; Male; Mice; Molecular Targeted Therapy; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Theranostic Nanomedicine; Xenograft Model Antitumor Assays | 2018 |
Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease.
Topics: Animals; B7-H1 Antigen; Bevacizumab; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Immunotherapy; Kidney Neoplasms; Mammary Neoplasms, Animal; Mice; Neoadjuvant Therapy; Neovascularization, Pathologic; Paclitaxel; Sunitinib | 2019 |
Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines.
Topics: Angiogenesis Inhibitors; Animals; Cell Survival; Deoxycytidine; Gemcitabine; Hep G2 Cells; Heparin, Low-Molecular-Weight; Human Umbilical Vein Endothelial Cells; Humans; Lipids; Liver Neoplasms; Mice; Microscopy, Fluorescence; Nanomedicine; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Transplantation, Heterologous | 2019 |
Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis.
Topics: Animals; Apoptosis; Benzothiazoles; Bromobenzenes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Copper; Copper Transport Proteins; Copper-Transporting ATPases; Female; Fluorobenzenes; Gene Expression Regulation, Neoplastic; Humans; Mice; Molecular Chaperones; Molybdenum; Neovascularization, Pathologic; Oxidative Stress; Paclitaxel; Small Molecule Libraries; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Placenta Growth Factor; Ramucirumab; Retrospective Studies; Stomach Neoplasms | 2019 |
Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Cell Proliferation; Doxorubicin; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Ligands; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neovascularization, Pathologic; Paclitaxel; Receptors, Interleukin-8B; Tumor Burden | 2013 |
Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model.
Topics: Administration, Oral; Angioplasty, Balloon; Animals; Aorta; Aortic Diseases; Apoptosis; Blood Glucose; Cilostazol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Drug-Eluting Stents; Endothelial Cells; Intercellular Adhesion Molecule-1; Male; Neovascularization, Pathologic; Paclitaxel; Phosphodiesterase 3 Inhibitors; Prosthesis Design; Rats; Rats, Sprague-Dawley; Tetrazoles; Thrombosis; Time Factors; Vascular Cell Adhesion Molecule-1; von Willebrand Factor; Wound Healing | 2013 |
Inhibitory effect of paclitaxel and rapamycin individual and dual drug-loaded polymeric micelles in the angiogenic cascade.
Topics: Angiogenesis Inhibitors; Apoptosis; Cell Movement; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Micelles; Neovascularization, Pathologic; Paclitaxel; Particle Size; Polyethylene Glycols; Sirolimus | 2013 |
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.
Topics: Antineoplastic Agents; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Coculture Techniques; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; MicroRNAs; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
Topics: Amides; Angiogenesis Inhibitors; Animals; Blood Vessels; Cell Cycle; Cell Movement; Cell Proliferation; Chickens; Chorioallantoic Membrane; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; Drugs, Chinese Herbal; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Male; Mice, Nude; Microtubules; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Podophyllotoxin; Pyridines; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2013 |
Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy.
Topics: Algorithms; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Artifacts; Bevacizumab; Body Water; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Imaging; MCF-7 Cells; Mice; Mice, SCID; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2014 |
Static magnetic fields increase tumor microvessel leakiness and improve antitumoral efficacy in combination with paclitaxel.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Disease Models, Animal; Endothelial Cells; Leukocytes; Magnetic Fields; Male; Mesocricetus; Microcirculation; Microscopy, Fluorescence; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Permeability | 2014 |
Ultrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles for the treatment of intraperitoneal ovarian cancer xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Proliferation; Drug Delivery Systems; Female; Humans; Immunoenzyme Techniques; Injections, Intraperitoneal; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Microbubbles; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Receptors, LHRH; Tumor Cells, Cultured; Ultrasonics; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Vascular-targeted agents for the treatment of angiosarcoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Axitinib; Bevacizumab; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Movement; Doxorubicin; Everolimus; Hemangiosarcoma; Humans; Imidazoles; Indazoles; Neovascularization, Pathologic; Paclitaxel; Protein Array Analysis; Sirolimus; Vascular Endothelial Growth Factor A | 2014 |
Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell-Derived Microparticles; Female; Flow Cytometry; Gene Knockdown Techniques; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Osteopontin; Paclitaxel | 2014 |
Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI.
Topics: Albumins; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Contrast Media; Female; Gadolinium DTPA; Humans; Magnetic Resonance Angiography; Mice; Mice, SCID; Neovascularization, Pathologic; Paclitaxel; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma.
Topics: Animals; Cell Line; Drug Delivery Systems; Glioma; Green Fluorescent Proteins; Human Umbilical Vein Endothelial Cells; Humans; In Situ Nick-End Labeling; Mice; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Recombinant Fusion Proteins | 2014 |
iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas.
Topics: Administration, Intravenous; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Collagen; Coumarins; Drug Combinations; Endocytosis; Glioma; Human Umbilical Vein Endothelial Cells; Humans; Kaplan-Meier Estimate; Lactic Acid; Laminin; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proteoglycans; Rats; Rats, Sprague-Dawley; Spectroscopy, Near-Infrared; Thiazoles; Tissue Distribution; Treatment Outcome | 2014 |
Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Hemoglobins; Humans; Mammary Glands, Human; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Spectrophotometry, Infrared; Triple Negative Breast Neoplasms; Vascular Remodeling | 2014 |
Thermosensitive hydrogel used in dual drug delivery system with paclitaxel-loaded micelles for in situ treatment of lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Cell Proliferation; Drug Delivery Systems; Hydrogels; Lung Neoplasms; Micelles; Neovascularization, Pathologic; Paclitaxel; Particle Size | 2014 |
The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma.
Topics: Adenosine; Animals; Antineoplastic Agents; Cell Physiological Phenomena; Disease Progression; Drug Screening Assays, Antitumor; Humans; Inosine; Melanoma; Mice; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Receptor, Adenosine A3; Tumor Cells, Cultured | 2014 |
Src inhibition potentiates antitumoral effect of paclitaxel by blocking tumor-induced angiogenesis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Fluorescent Antibody Technique; Focal Adhesion Kinase 1; Humans; Immunoenzyme Techniques; Male; Mice; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Protein Kinase Inhibitors; src-Family Kinases; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chemokine CCL21; Cytokines; Cytotoxicity, Immunologic; Disease Models, Animal; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Melanoma, Experimental; Mice; Neoplasms; Neovascularization, Pathologic; Paclitaxel; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; Tumor Burden | 2014 |
Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Dinoprostone; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrazoles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Extravascular red blood cells and hemoglobin promote tumor growth and therapeutic resistance as endogenous danger signals.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Erythrocytes; Hemoglobins; Hemorrhage; Inflammation; Interleukin-1beta; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Neovascularization, Pathologic; Oxidative Stress; Paclitaxel; Reactive Oxygen Species; Transcription Factor RelA; Tumor Microenvironment | 2015 |
Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.
Topics: Adjuvants, Pharmaceutic; Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Endothelial Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Maximum Tolerated Dose; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Xenograft Model Antitumor Assays | 2014 |
Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic paclitaxel.
Topics: Administration, Metronomic; Animals; Anti-Arrhythmia Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Verapamil; Xenograft Model Antitumor Assays | 2015 |
MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an (18)F labeled RGD-based probe in SKOV-3 xenograft-bearing mice.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Female; Humans; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Peptides, Cyclic; Polyethylene Glycols; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution; Xenograft Model Antitumor Assays | 2015 |
Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Topics: Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Movement; Cell Survival; Collagen; Coumarins; Drug Combinations; Drug Delivery Systems; Endocytosis; Female; Human Umbilical Vein Endothelial Cells; Humans; Intracellular Signaling Peptides and Proteins; Laminin; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Molecular Sequence Data; Nanomedicine; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Peptides; Proteoglycans; Rats, Sprague-Dawley; Subcutaneous Tissue; Thiazoles; Xenograft Model Antitumor Assays | 2015 |
Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Diphosphonates; Female; High-Throughput Screening Assays; Humans; Imidazoles; Immunohistochemistry; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; p21-Activated Kinases; p38 Mitogen-Activated Protein Kinases; Paclitaxel; rac1 GTP-Binding Protein; Signal Transduction; Transfection; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Blood Cell Count; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Neutrophils; Paclitaxel; Platinum; Vascular Endothelial Growth Factor A | 2015 |
In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Cell Line; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Humans; Male; Mice; Micelles; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Polyethylene Glycols; Polyglactin 910; Tissue Distribution; Tumor Burden | 2015 |
Blocking IL1β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Macrophages; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Receptors, Interleukin-1; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Burden | 2015 |
Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Myristoylated Alanine-Rich C Kinase Substrate; Neovascularization, Pathologic; Paclitaxel; Peptide Fragments; Phosphorylation; RNA Interference; RNA, Small Interfering; Tubulin Modulators | 2015 |
IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Topics: Animals; Annexin A1; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Peptide Fragments; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Multifunctional Tandem Peptide Modified Paclitaxel-Loaded Liposomes for the Treatment of Vasculogenic Mimicry and Cancer Stem Cells in Malignant Glioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Glioma; Liposomes; Mice, Inbred BALB C; Neoplastic Stem Cells; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Treatment Outcome | 2015 |
Combined Delivery and Anti-Cancer Activity of Paclitaxel and Curcumin Using Polymeric Micelles.
Topics: Animals; Antineoplastic Agents; Apoptosis; Colonic Neoplasms; Curcumin; Drug Carriers; Drug Delivery Systems; Female; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Micelles; Microcirculation; Microscopy, Fluorescence; Neovascularization, Pathologic; NF-kappa B; Paclitaxel; Polymers; Zebrafish | 2015 |
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Topics: Administration, Metronomic; Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays | 2015 |
miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neovascularization, Pathologic; Paclitaxel; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2016 |
Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate | 2016 |
Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy.
Topics: Animals; Cell Line, Tumor; Drug Carriers; Glioma; Lipids; Mice; Nanoparticles; Neovascularization, Pathologic; NIH 3T3 Cells; Octreotide; Paclitaxel; Rats | 2016 |
Tumor priming using metronomic chemotherapy with neovasculature-targeted, nanoparticulate paclitaxel.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Delivery Systems; Female; Heterografts; Humans; Lactates; Mice; Mice, Nude; Nanoparticles; Neoplasm Transplantation; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Polyethylene Glycols; Tumor Microenvironment | 2016 |
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Splenic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Chemotherapy enhances tumor vascularization via Notch signaling-mediated formation of tumor-derived endothelium in breast cancer.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Bridged-Ring Compounds; Doxorubicin; Endothelium, Vascular; Female; Humans; MCF-7 Cells; Mice, Nude; Microvessels; Neoplasm Proteins; Neovascularization, Pathologic; Paclitaxel; Receptors, Notch; RNA Interference; Signal Transduction; Specific Pathogen-Free Organisms; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cdh1 Proteins; Cell Line, Tumor; Cisplatin; Cytokines; Endoglin; Female; Humans; Interferon-gamma; Interleukin-12 Subunit p35; Killer Cells, Natural; Lung Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-3 | 2016 |
Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Microscopy, Fluorescence; Nanomedicine; Nanoparticles; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Perfusion; Receptor, Platelet-Derived Growth Factor beta; Tumor Microenvironment | 2016 |
Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts.
Topics: Administration, Metronomic; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Neovascularization, Pathologic; Paclitaxel; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2017 |
Combined Tumor- and Neovascular-"Dual Targeting" Gene/Chemo-Therapy Suppresses Tumor Growth and Angiogenesis.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Mice; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Paclitaxel | 2016 |
Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aptamers, Nucleotide; Breast; Breast Neoplasms; Drug Carriers; Drug Delivery Systems; Epithelial Cell Adhesion Molecule; Female; Human Umbilical Vein Endothelial Cells; Humans; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Rats, Sprague-Dawley | 2017 |
Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides; Tumor Burden | 2017 |
MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; MicroRNAs; Neoplastic Stem Cells; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Receptor, Notch3; Signal Transduction; Time Factors; Transfection | 2017 |
Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capillaries; Capillary Permeability; Cations; Cisplatin; Cricetinae; Liposomes; Male; Melanoma, Experimental; Mesocricetus; Neovascularization, Pathologic; Paclitaxel | 2008 |
A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biological Assay; Blood Coagulation; Breast Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fibrin; Fluorouracil; Humans; Methotrexate; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Thrombin; Vincristine | 2008 |
Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth.
Topics: Animals; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Down-Regulation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; In Situ Nick-End Labeling; Mice; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Subcutaneous Tissue; Xenograft Model Antitumor Assays | 2009 |
Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.
Topics: Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Immunohistochemistry; Liposomes; Lymph Nodes; Lymphatic Metastasis; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Tumor Burden; Vitamin E | 2009 |
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; DNA; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Genotype; Humans; Hypertension; Liver Neoplasms; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Polymorphism, Genetic; Vascular Endothelial Growth Factor A | 2009 |
Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cisplatin; Cricetinae; Deoxycytidine; Drug Administration Schedule; Drug Delivery Systems; Gemcitabine; Humans; Immunohistochemistry; Lipopeptides; Liposomes; Lung Neoplasms; Male; Mice; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms | 2010 |
Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma 256, Walker; Cell Line; Cell Migration Inhibition; Cell Proliferation; Docetaxel; Endothelial Cells; Female; Humans; Neovascularization, Pathologic; Paclitaxel; Rats; Rats, Wistar; Stem Cells; Taxoids | 2009 |
Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor.
Topics: Alphavirus Infections; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Membrane Permeability; Combined Modality Therapy; Cricetinae; Drug Delivery Systems; Female; Genetic Vectors; Humans; Mice; Mice, SCID; Neovascularization, Pathologic; Neuroblastoma; Oncolytic Virotherapy; Ovarian Neoplasms; Paclitaxel; Sindbis Virus; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Piperidines; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endothelial Cells; Female; Lymphangiogenesis; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; Thrombospondin 1; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Endothelium, Vascular; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Longitudinal Studies; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pericytes; Proto-Oncogene Proteins c-sis; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.
Topics: Aldehydes; Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Cell Movement; Cells, Cultured; Drug Carriers; Drug Delivery Systems; Female; Humans; Lactic Acid; Mice; Mice, Inbred BALB C; Molecular Structure; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Particle Size; Peptides; Polyesters; Polyethylene Glycols; Polymers | 2010 |
Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis.
Topics: Animals; Antineoplastic Agents; Cancer Vaccines; Humans; Lymphocyte Depletion; Mice; Neoplasms; Neovascularization, Pathologic; Paclitaxel; T-Lymphocytes, Regulatory | 2010 |
A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Endocytosis; Endothelial Cells; Humans; Immunohistochemistry; Liver Neoplasms; Male; Mice; Nanocapsules; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Stilbenes | 2010 |
Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Xenograft Model Antitumor Assays | 2010 |
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Administration Schedule; Endothelial Cells; Etoposide; Humans; In Vitro Techniques; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide | 2010 |
Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Availability; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Intestinal Absorption; Intestinal Mucosa; Isonicotinic Acids; Male; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Permeability; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Breast Neoplasms; Cells, Cultured; Endostatins; Endothelium, Vascular; Female; Genetic Therapy; Humans; Lung Neoplasms; Mice; Mutant Proteins; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Polyploidy; Recombinant Proteins | 2011 |
Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor.
Topics: Animals; Benzamides; Capillary Permeability; Carbon Isotopes; Humans; Hypoxia-Inducible Factor 1; Imatinib Mesylate; L-Lactate Dehydrogenase; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A | 2010 |
In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Xenograft Model Antitumor Assays | 2011 |
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
Topics: Animals; Antigens, CD; Ascites; Cadherins; Cell Adhesion; Cell Line, Tumor; Drug Synergism; Endothelial Cells; Female; Humans; Interleukin-6; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Receptors, Interleukin-6; Recombinant Fusion Proteins; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2011 |
Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cathepsin B; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Humans; Integrins; Mice; Mice, Inbred BALB C; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Polyglutamic Acid; Rats; Rats, Wistar | 2011 |
Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cisplatin; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Mice; Mice, Nude; Naltrexone; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2011 |
G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist.
Topics: Animals; Antineoplastic Agents; Benzylamines; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclams; Drug Combinations; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Immunohistochemistry; Inflammatory Breast Neoplasms; Injections, Intraperitoneal; Matrix Metalloproteinase 2; Mice; Mice, Knockout; Neovascularization, Pathologic; Paclitaxel; Receptors, CXCR4; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
Dairy milk fat augments paclitaxel therapy to suppress tumour metastasis in mice, and protects against the side-effects of chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cachexia; Colonic Neoplasms; Dietary Fats; Dietary Supplements; Female; gamma-Glutamyltransferase; Mice; Mice, Inbred BALB C; Milk; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Soybean Oil; Time Factors | 2011 |
A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Proteins; Bevacizumab; Cell Line, Tumor; Diphtheria Toxin; Female; Growth Inhibitors; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2011 |
Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Microvessels; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Predictive Value of Tests; Prognosis; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel.
Topics: Animals; Carbocyanines; Cell Line; Cell Proliferation; Female; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Micelles; Microscopy, Confocal; Microscopy, Electron, Transmission; Microvessels; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Particle Size; Peptides; Polymers; Tissue Distribution; Xenograft Model Antitumor Assays | 2012 |
Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Mesenchymal Stem Cells; Mice; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2011 |
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2012 |
MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Topics: Angiogenesis Inhibitors; Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Corrosion Casting; Dose-Response Relationship, Drug; Female; Fluorescence; HEK293 Cells; Humans; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Phosphorylation; Receptor, TIE-2; Retinal Neovascularization; Time Factors; Transfection; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2012 |
Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.
Topics: Animals; Carcinoma; Cell Line, Tumor; Combined Modality Therapy; Female; Genetic Therapy; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2012 |
Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cathepsin B; Cell Cycle; Cell Line, Tumor; Citrulline; Dipeptides; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Tumor Burden; Valine | 2012 |
The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Female; Humans; Interferon-gamma; Interleukin-12; Mice; Mice, 129 Strain; Mice, Inbred BALB C; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Recombinant Fusion Proteins; Single-Chain Antibodies; Tissue Distribution; Treatment Outcome; Tumor Burden | 2012 |
Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Topics: Acetamides; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dasatinib; Drug Synergism; Estrogen Receptor alpha; Female; Focal Adhesion Kinase 1; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Neoplasm Invasiveness; Neoplasm Micrometastasis; Neovascularization, Pathologic; Paclitaxel; Peptidomimetics; Pyridines; Pyrimidines; Receptor, ErbB-2; Receptors, Progesterone; src-Family Kinases; Thiazoles; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Movement; Disease Models, Animal; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2012 |
Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Humans; Immunoenzyme Techniques; Indoles; Liposomes; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; Pericytes; Polyethylene Glycols; Pyrroles; Solubility; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Targeted delivery of paclitaxel to EphA2-expressing cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drug Delivery Systems; Female; Gene Expression; Humans; Male; Mice; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Peptides; Receptor, EphA2; Transplantation, Homologous; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Breast Neoplasms; Capecitabine; Carboplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neovascularization, Pathologic; Paclitaxel; ROC Curve; Spectroscopy, Near-Infrared; Trastuzumab; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice.
Topics: Animals; Cell Communication; Cell Growth Processes; Cell Line, Tumor; Disease Models, Animal; Humans; Leukemia; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Xenograft Model Antitumor Assays | 2013 |
Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
Topics: Antineoplastic Agents; bcl-X Protein; Blotting, Western; Bridged-Ring Compounds; CDC2 Protein Kinase; Cell Cycle; Cell Death; Cell Division; Cell Nucleus; Cell Separation; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Growth Factors; Fibroblast Growth Factor 2; Flow Cytometry; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Maturation-Promoting Factor; Mitosis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Subcellular Fractions; Taxoids; Time Factors; Tubulin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carboplatin; Cell Survival; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Organic Chemicals; Ovarian Neoplasms; Paclitaxel; Protein Kinase C; Protein Kinase C beta; Regional Blood Flow; Transplantation, Heterologous | 2002 |
Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured | 2002 |
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
Topics: Androgens; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Disease Models, Animal; Drug Therapy, Combination; Endothelial Growth Factors; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Cell Division; Drug Synergism; Endothelin Receptor Antagonists; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2002 |
Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Movement; Cells, Cultured; Centrosome; Collagen; Docetaxel; Drug Combinations; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; In Vitro Techniques; Laminin; Mice; Mice, Inbred C57BL; Microtubules; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Proteoglycans; Rats; Taxoids; Tumor Cells, Cultured; Umbilical Veins; Xenograft Model Antitumor Assays | 2002 |
Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants.
Topics: Amides; Animals; Aorta, Thoracic; Cell Division; Cell Line; Drug Synergism; Enzyme Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, SCID; Microscopy, Fluorescence; Myosin-Light-Chain Phosphatase; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphoprotein Phosphatases; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Pyridines; Rabbits; rho-Associated Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Transitional Cell; Cyclohexanes; Docetaxel; Drug Synergism; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes; Taxoids; Time Factors; Transplantation, Heterologous; Urinary Bladder Neoplasms | 2003 |
Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Capsules; Cations; Cell Division; Endothelium, Vascular; Humans; Liposomes; Melanoma, Experimental; Mice; Mice, SCID; Mitotic Index; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Tumor Cells, Cultured | 2003 |
Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Division; Drug Synergism; Endothelial Growth Factors; Endothelin Receptor Antagonists; Female; Growth Inhibitors; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2003 |
Anti-invasion and anti-angiogenesis effect of taxol and camptothecin on melanoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Adhesion; Cell Movement; Chick Embryo; Collagenases; Humans; Melanoma, Experimental; Mice; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Tumor Cells, Cultured | 2003 |
Targeting angiogenic processes by combination low-dose paclitaxel and radiation therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Chemotaxis; Endothelial Cells; Humans; In Vitro Techniques; Mice; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Radiation-Sensitizing Agents; Rats; Rats, Sprague-Dawley | 2003 |
Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Probability; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Reference Values; Trastuzumab; Tumor Cells, Cultured | 2003 |
Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.
Topics: Angiopoietin-1; Angiopoietin-2; Antineoplastic Agents, Phytogenic; Cell Division; Epithelium; Female; Gene Expression Regulation, Neoplastic; Humans; Neovascularization, Pathologic; Ovarian Neoplasms; Ovary; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2004 |
Taxol inhibits melanoma metastases through apoptosis induction, angiogenesis inhibition, and restoration of E-cadherin and nm23 expression.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cadherins; Coloring Agents; Eosine Yellowish-(YS); Fluorescent Dyes; Hematoxylin; Immunohistochemistry; In Situ Hybridization; In Situ Nick-End Labeling; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Microscopy, Electron; Neovascularization, Pathologic; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Paclitaxel; Protein Biosynthesis; RNA, Messenger; Vascular Endothelial Growth Factor A | 2003 |
Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Fibroblast Growth Factor 2; Humans; Interleukin-8; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Models, Biological; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A | 2003 |
Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.
Topics: Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Blood Proteins; Cell Division; Chemistry, Pharmaceutical; Docetaxel; Drug Interactions; Endothelium, Vascular; Excipients; Glycerol; Humans; In Vitro Techniques; Male; Neovascularization, Pathologic; Paclitaxel; Pharmaceutical Vehicles; Polysorbates; Protein Binding; Rats; Rats, Sprague-Dawley; Taxoids | 2004 |
Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature.
Topics: Animals; Cricetinae; Drug Carriers; Erythrocytes; In Situ Nick-End Labeling; Liposomes; Male; Melanoma, Experimental; Mesocricetus; Microcirculation; Neovascularization, Pathologic; Paclitaxel; Regional Blood Flow | 2004 |
Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study.
Topics: Angiogenesis Inhibitors; Animals; Body Weight; Male; Necrosis; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Rats; Vascular Endothelial Growth Factor A | 2004 |
Angiogenesis gene expression profiling in xenograft models to study cellular interactions.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antineoplastic Agents; Base Sequence; Disease Models, Animal; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Molecular Sequence Data; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Skin Neoplasms; Transplantation, Heterologous | 2004 |
Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Administration Schedule; Female; Growth Inhibitors; Humans; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Xenograft Model Antitumor Assays | 2004 |
Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Death; Cell Division; Cell Proliferation; Cells, Cultured; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Endothelium, Vascular; G2 Phase; Humans; Intracellular Membranes; Laminin; Membrane Potentials; Microcirculation; Microscopy, Fluorescence; Microtubules; Mitochondria; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Proteoglycans; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Time Factors | 2004 |
Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Hemoglobins; Humans; Middle Aged; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Prognosis; Treatment Outcome | 2004 |
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Female; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Platelet-Derived Growth Factor; Pyrimidines; Radiography; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Time Factors | 2005 |
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzimidazoles; Cell Growth Processes; Female; Glioblastoma; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Quinolines; Rats; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Xenograft Model Antitumor Assays | 2005 |
Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Cell Line; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Microtubules; Neoplasms; Neovascularization, Pathologic; Paclitaxel | 2005 |
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factors; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Paclitaxel; Xenograft Model Antitumor Assays | 2005 |
Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Line, Tumor; Cisplatin; Endothelin A Receptor Antagonists; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Time Factors; Xenograft Model Antitumor Assays | 2004 |
The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Retinoid X Receptors; Survival Rate; Tetrahydronaphthalenes; Umbilical Veins | 2005 |
Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Capillary Permeability; Cell Growth Processes; Cell Line, Tumor; ErbB Receptors; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Protein Kinase Inhibitors; Purines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2005 |
Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Green Fluorescent Proteins; Humans; Immunohistochemistry; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Peritoneal Neoplasms; Plasmids; Platelet Endothelial Cell Adhesion Molecule-1; Stomach Neoplasms; Survival Analysis; Survival Rate; Transfection; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Drug Administration Schedule; Drug Synergism; Fluorescent Antibody Technique; Imatinib Mesylate; Male; Mice; Mice, SCID; Models, Animal; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Piperazines; Prostatic Neoplasms; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Treatment Failure | 2005 |
Albumin-bound nanoparticle paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Nanostructures; Nanotechnology; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Prodrugs | 2005 |
Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Biopsy; Dose-Response Relationship, Drug; Female; Fibrosis; Humans; Male; Mice; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Phenotype; Scleroderma, Systemic; Signal Transduction; Smad Proteins; Transforming Growth Factor beta; Transplantation, Heterologous | 2005 |
YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Mice; Mice, Nude; Morpholines; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Quinolines; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Diffusion; Drug Carriers; Drug Stability; Endothelial Cells; Hydrogels; Injections, Subcutaneous; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Photochemistry; Skin Neoplasms | 2005 |
The inhibition of angiogenesis by antisense oligonucleotides to clusterin.
Topics: Apoptosis; Base Sequence; bcl-X Protein; Camptothecin; Cell Line; Cell Survival; Clusterin; Collagen; DNA Fragmentation; Doxorubicin; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Humans; Inhibitor of Apoptosis Proteins; Laminin; Microtubule-Associated Proteins; Neoplasm Proteins; Neovascularization, Pathologic; Oligonucleotides, Antisense; Paclitaxel; Proteoglycans; Survivin; Thionucleotides | 2005 |
[Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice].
Topics: Animals; Antigens, CD34; Cell Line, Tumor; Humans; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Transplantation, Heterologous | 2005 |
Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; Capsules; Contrast Media; Cricetinae; Gadolinium DTPA; Lipids; Magnetic Resonance Imaging; Melanoma; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Tumor Cells, Cultured | 2006 |
EndoTAG-1. MediGene.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Liposomes; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms | 2005 |
Antitumor effects of IDN5109 on head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Neovascularization, Pathologic; Paclitaxel; Taxoids | 2006 |
Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice.
Topics: Alkanes; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Caspases; Cell Cycle; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Female; Humans; Immunohistochemistry; Lactones; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Pyrones; Xenograft Model Antitumor Assays | 2006 |
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Quinazolines; Thiazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2006 |
The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line; Cell Line, Tumor; Cells, Cultured; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Endothelial Cells; Female; Immunohistochemistry; Indoles; Laminin; Mice; Mice, Nude; Myocytes, Smooth Muscle; Neovascularization, Pathologic; Neovascularization, Physiologic; Oxindoles; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Protein-Tyrosine Kinases; Proteoglycans; Pyrroles; Xenograft Model Antitumor Assays | 2006 |
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.
Topics: Angiostatins; Animals; Antineoplastic Agents; Cell Line, Tumor; Clonal Anergy; Cyclohexanes; Cyclophosphamide; Down-Regulation; Endostatins; Endothelial Cells; Endothelium; Humans; Intercellular Adhesion Molecule-1; Leukocytes; Mice; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Peptides; Proteins; Sesquiterpenes; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2006 |
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Lymphatic Metastasis; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Tibia; Tumor Cells, Cultured | 2006 |
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
Topics: Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta; Bridged-Ring Compounds; Cell Proliferation; Endothelium, Vascular; Female; Humans; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Rats; Surface-Active Agents; Taxoids | 2006 |
Is it time for some new approaches for treating advanced ovarian cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Failure | 2006 |
[Combined low-dose chemotherapy inhibiting angiogenesis and growth of Lewis lung cancinoma xenografts in mice].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cyclophosphamide; Female; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Paclitaxel; Random Allocation; Vascular Endothelial Growth Factor A | 2006 |
Potential predictors of chemotherapy response in ovarian cancer--how do we define chemosensitivity?
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Neovascularization, Pathologic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Predictive Value of Tests; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A | 2007 |
Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Basement Membrane; Breast Neoplasms; Cell Growth Processes; Chick Embryo; Collagen Type IV; Dose-Response Relationship, Immunologic; Drug Synergism; Epitopes; Extracellular Matrix; Female; Humans; Immunoglobulin G; Immunoglobulin M; Male; Melanoma; Mice; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1 | 2006 |
Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF.
Topics: Animals; Apoptosis; Cells, Cultured; Drug Therapy, Combination; Electrophysiology; Endothelial Cells; Humans; Injections, Intramuscular; Lectins; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Paclitaxel; Peripheral Nervous System Diseases; Phosphatidylinositol 3-Kinases; Plasmids; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Renal Circulation; Thalidomide; Vasa Nervorum; Vascular Endothelial Growth Factor A | 2007 |
VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.
Topics: Animals; Antibodies; Antibody Formation; Cancer Vaccines; Cell Line, Tumor; Colorectal Neoplasms; Female; HT29 Cells; Humans; Immune Sera; Immunization; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Rhabdomyosarcoma; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Tetrazoles; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Carcinoma, Squamous Cell; Cell Proliferation; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Paclitaxel; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides.
Topics: Animals; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cyclin D1; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neovascularization, Pathologic; Oligodeoxyribonucleotides; Paclitaxel; Phosphorylation; Protein Conformation; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; STAT3 Transcription Factor; Survivin; Vascular Endothelial Growth Factor A | 2007 |
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endothelin A Receptor Antagonists; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Xenograft Model Antitumor Assays | 2007 |
Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Chick Embryo; Chlorocebus aethiops; Combined Modality Therapy; COS Cells; Endostatins; Female; Gene Expression; Genetic Therapy; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; Recombinant Proteins | 2008 |
Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mice; Mice, Nude; Mitosis; Necrosis; Neovascularization, Pathologic; Organophosphorus Compounds; Paclitaxel; Survival Rate; Treatment Outcome; Xenograft Model Antitumor Assays | 2007 |
[Inhibitory effect of huangqi and dangshen extraction with pacilitaxel on metastasis and angiogenesis on mouse Lewis lung carcinoma model].
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Codonopsis; Drugs, Chinese Herbal; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel | 2008 |
Taxol and embryonic development in the chick.
Topics: Abnormalities, Drug-Induced; Animals; Chick Embryo; Dose-Response Relationship, Drug; Neovascularization, Pathologic; Paclitaxel; Time Factors | 1994 |
Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol.
Topics: Animals; Antibody Formation; Arthritis, Experimental; Autoimmune Diseases; Collagen; Cyclohexanes; Drug Therapy, Combination; Female; Immunity, Cellular; Microtubules; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Rats; Sesquiterpenes | 1994 |
Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid).
Topics: Animals; Chick Embryo; Delayed-Action Preparations; In Vitro Techniques; Lactates; Lactic Acid; Microscopy, Electron, Scanning; Microspheres; Neovascularization, Pathologic; Paclitaxel; Polymers; Polyvinyls | 1995 |
Taxol encapsulation in poly(epsilon-caprolactone) microspheres.
Topics: Allantois; Animals; Chick Embryo; Chorion; Delayed-Action Preparations; Microspheres; Neovascularization, Pathologic; Paclitaxel; Polyesters | 1995 |
Eighty-seventh annual meeting of the American Association for Cancer Research. Washington, D,C., 20-24 April 1996.
Topics: Aged; Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Genes, p53; Genes, Tumor Suppressor; Humans; Hyperplasia; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Research; Survival Rate | 1996 |
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carboplatin; Carcinoma, Lewis Lung; Cell Survival; Colony-Forming Units Assay; Cyclohexanes; Drug Synergism; Drug Therapy, Combination; Female; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Minocycline; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes | 1998 |
Taxol involution of collagen-induced arthritis: ultrastructural correlation with the inhibition of synovitis and neovascularization.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arthritis, Rheumatoid; Collagen; Corrosion Casting; Disease Models, Animal; Female; Humans; Microscopy, Electron; Microscopy, Electron, Scanning; Neovascularization, Pathologic; Paclitaxel; Rats; Rats, Inbred Strains; Synovial Membrane; Synovitis | 1998 |
The microtubule-affecting drug paclitaxel has antiangiogenic activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Movement; Cells, Cultured; Cisplatin; Collagen; Drug Combinations; Endothelium, Vascular; Laminin; Male; Mice; Mice, Inbred C57BL; Microtubules; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Proteoglycans | 1996 |
Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured hepatocytes and microsomes.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cells, Cultured; Cyclohexanes; Cyclophosphamide; Drug Interactions; Liver; Macaca mulatta; Microsomes, Liver; Minocycline; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes; Tissue Distribution | 1999 |
Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Organic Chemicals; Paclitaxel; Transplantation, Heterologous; Treatment Outcome; Tumor Cells, Cultured | 1999 |
[Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere)].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Capillaries; Carcinoma, Squamous Cell; Docetaxel; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Taxoids; Tumor Cells, Cultured | 1999 |
Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Cell Cycle Proteins; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Cyclin-Dependent Kinase Inhibitor p27; Female; Growth Substances; Humans; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Transplantation; Neovascularization, Pathologic; Oligonucleotides, Antisense; Paclitaxel; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2000 |
Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Apoptosis; Carcinoma, Transitional Cell; Cell Division; Endothelial Growth Factors; Fibroblast Growth Factor 2; Humans; Interleukin-8; Lymphokines; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Paclitaxel; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2000 |
Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Transitional Cell; Cell Division; Cetuximab; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Immunologic; Down-Regulation; Endothelial Growth Factors; Endothelium; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Inhibitory Concentration 50; Interleukin-8; Lymphatic Metastasis; Lymphokines; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Fluorescence; Neoplasm Transplantation; Neovascularization, Pathologic; Organ Size; Paclitaxel; RNA, Messenger; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Endothelial Growth Factors; Female; Humans; Lymphokines; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; RNA, Messenger; Thalidomide; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Division; Cell Hypoxia; Cell Movement; Cell Survival; Drug Synergism; Endothelial Growth Factors; Endothelium, Vascular; Humans; Lymphokines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Polyenes; Polyunsaturated Alkamides; Thyroid Neoplasms; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carboplatin; Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Tumor Suppressor Protein p53 | 2001 |
Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis.
Topics: Allylamine; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Benzothiazoles; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Synergism; Drug Therapy, Combination; Endothelial Growth Factors; Humans; Lactams, Macrocyclic; Lung Neoplasms; Lymphokines; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Quinones; Tumor Cells, Cultured; Tyrphostins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Biopsy; Blood Vessels; Blotting, Northern; Cadherins; Carcinoma, Transitional Cell; Cell Movement; Collagen; Collagenases; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Interferon-alpha; Interleukin-8; Laminin; Lymphokines; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Prognosis; Proteoglycans; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2001 |
Biological basis for chemo-radiotherapy interactions.
Topics: Antineoplastic Agents; Apoptosis; Cell Transformation, Neoplastic; Cisplatin; Combined Modality Therapy; Deoxycytidine; DNA Adducts; DNA Repair; Docetaxel; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Paclitaxel; Radiotherapy; Taxoids | 2002 |
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta; Breast Neoplasms; Cell Movement; Coumarins; Cyclophosphamide; Drug Synergism; Endothelium, Vascular; Female; Fluorouracil; Growth Inhibitors; Humans; Isocoumarins; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2002 |
HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Endothelial Growth Factors; Endothelium, Vascular; Extraembryonic Membranes; Female; Fibroblast Growth Factor 2; HIV Protease Inhibitors; Humans; Indinavir; Lymphokines; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Saquinavir; Sarcoma, Kaposi; Skin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Quantitative analysis of angiogenesis using confocal laser scanning microscopy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Capillaries; Carcinoma, Non-Small-Cell Lung; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Microscopy, Confocal; Microscopy, Fluorescence; Muscle, Skeletal; Neoplasm Transplantation; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Xenograft Model Antitumor Assays | 2001 |
Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
Topics: Androgens; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Blood Vessels; Cell Cycle Proteins; Cell Division; Cetuximab; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Humans; Interleukin-8; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Prostatic Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins; Tyrosine; Up-Regulation; Xenograft Model Antitumor Assays | 2002 |
Assessment of antiangiogenic effect using 99mTc-EC-endostatin.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Collagen; Cysteine; Endostatins; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Interleukin-8; Lymphokines; Mammary Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Peptide Fragments; Radionuclide Imaging; Rats; Rats, Inbred F344; Technetium; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
A mouse model for the study of factors affecting angiogenesis.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Docetaxel; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Humans; Ifosfamide; Injections, Subcutaneous; Mice; Neovascularization, Pathologic; Paclitaxel; Prostheses and Implants; Surgical Sponges; Taxoids | 2002 |